secwatch / observer
8-K filed December 22, 2022, 6:59 PM ET ticker TSHA CIK 0001806310
leadership confidence high sentiment neutral materiality 0.50

CEO RA Session II resigns; Chairman Sean Nolan appointed CEO; Sukumar Nagendran named President and Head of R&D

Taysha Gene Therapies, Inc.

item 5.02item 8.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Suyash Prasad

Chief Medical Officer
TSHA · Taysha Gene Therapies, Inc.
Effective
2022-12-16
Filed
December 22, 2022, 6:59 PM ET
Dr. Suyash Prasad’s title was changed from Chief Medical Officer and Head of Research and Development to Chief Medical Officer, effective as of Dr. Nagendran’s appointment.
Appointed

Sean Nolan

Chief Executive Officer
TSHA · Taysha Gene Therapies, Inc.
Effective
2022-12-16
Filed
December 22, 2022, 6:59 PM ET
On December 16, 2022, the Board appointed Sean Nolan as the Company’s Chief Executive Officer, effective as of the effective time of Mr. Session’s resignation.
Appointed

Sukumar Nagendran

President and Head of Research and Development
TSHA · Taysha Gene Therapies, Inc.
Effective
2022-12-16
Filed
December 22, 2022, 6:59 PM ET
On December 16, 2022, the Board appointed Dr. Sukumar Nagendran as the Company’s President and Head of Research and Development, effective immediately.
Departed

RA Session II

President and Chief Executive Officer
TSHA · Taysha Gene Therapies, Inc.
Effective
2022-12-16
Successor
Sean Nolan
Filed
December 22, 2022, 6:59 PM ET
On December 16, 2022, RA Session II, the President and Chief Executive Officer of Taysha Gene Therapies, Inc. (the “ Company ”), resigned from his operating role, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Suyash Prasad changed role as Chief Medical Officer at Taysha Gene Therapies, Inc..

Action
title changed
Role
Chief Medical Officer
Exact text from the filing
Dr. Suyash Prasad’s title was changed from Chief Medical Officer and Head of Research and Development to Chief Medical Officer, effective as of Dr. Nagendran’s appointment.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Sean Nolan was appointed as Chief Executive Officer at Taysha Gene Therapies, Inc..

Action
appointed
Role
Chief Executive Officer
Exact text from the filing
On December 16, 2022, the Board appointed Sean Nolan as the Company’s Chief Executive Officer, effective as of the effective time of Mr. Session’s resignation.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Sukumar Nagendran was appointed as President and Head of Research and Development at Taysha Gene Therapies, Inc..

Action
appointed
Role
President and Head of Research and Development
Exact text from the filing
On December 16, 2022, the Board appointed Dr. Sukumar Nagendran as the Company’s President and Head of Research and Development, effective immediately.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

RA Session II resigned as President and Chief Executive Officer at Taysha Gene Therapies, Inc..

Action
resigned
Role
President and Chief Executive Officer
Exact text from the filing
On December 16, 2022, RA Session II, the President and Chief Executive Officer of Taysha Gene Therapies, Inc. (the “ Company ”), resigned from his operating role, effective immediately.
View on SEC.gov

Taysha Gene Therapies, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-22-311027
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.